Accord Logo

Intended for UK patients and members of the public

Imatinib Tablets

Active Ingredients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Imatinib Accord 100mg Film-coated Tablets

PL Number:
PLGB 20075/1282
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • 1)To register a change in the composition of the finished

    product by changing the tablet coating from Hypromellose 6

    cps (E464) to Polyvinyl alcohol- (E1203) and from Polyethylene

    glycol to Polyethylene glycol (E1521). Consequently, section

    6.1 of the SmPC and the PIL has been updated.

     

    2)To register a minor change in manufacturing process of

    finished product by changing the manufacturing process for

    coating solution preparation from non-aqueous coating solution to aqueous coating solution.

     

    3)To register a change in the specification parameters of the

    finished product by deletion of residual solvent test for

    Dichloromethane from finished product specification.

  • 1)To register a change in the composition of the finished

    product by changing the tablet coating from Hypromellose 6

    cps (E464) to Polyvinyl alcohol- (E1203) and from Polyethylene

    glycol to Polyethylene glycol (E1521). Consequently, section

    6.1 of the SmPC and the PIL has been updated.

     

    2)To register a minor change in manufacturing process of

    finished product by changing the manufacturing process for

    coating solution preparation from non-aqueous coating solution to aqueous coating solution.

     

    3)To register a change in the specification parameters of the

    finished product by deletion of residual solvent test for

    Dichloromethane from finished product specification.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Imatinib Accord 400mg Film-coated Tablets

PL Number:
PLGB 20075/1283
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • 1)To register a change in the composition of the finished

    product by changing the tablet coating from Hypromellose 6

    cps (E464) to Polyvinyl alcohol- (E1203) and from Polyethylene

    glycol to Polyethylene glycol (E1521). Consequently, section

    6.1 of the SmPC and the PIL has been updated.

     

    2)To register a minor change in manufacturing process of

    finished product by changing the manufacturing process for

    coating solution preparation from non-aqueous coating solution to aqueous coating solution.

     

    3)To register a change in the specification parameters of the

    finished product by deletion of residual solvent test for

    Dichloromethane from finished product specification.

  • 1)To register a change in the composition of the finished

    product by changing the tablet coating from Hypromellose 6

    cps (E464) to Polyvinyl alcohol- (E1203) and from Polyethylene

    glycol to Polyethylene glycol (E1521). Consequently, section

    6.1 of the SmPC and the PIL has been updated.

     

    2)To register a minor change in manufacturing process of

    finished product by changing the manufacturing process for

    coating solution preparation from non-aqueous coating solution to aqueous coating solution.

     

    3)To register a change in the specification parameters of the

    finished product by deletion of residual solvent test for

    Dichloromethane from finished product specification.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: